Clinical Advances in HR-Positive Breast Cancer

Clinical Advances in HR-Positive Breast Cancer The approval of cyclin-dependent kinase (CDK) 4/6 inhibitors for hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer (MBC) has permanently changed the treatment paradigm of this disease. Clinicians are faced with increasingly complex decision-making and must be educated on the optimal use of these agents in clinical practice. This Clinical Advances educational initiative will assist clinicians in making more informed choices for their patients by discussing recent data and real-world experiences on the efficacy and safety of CDK4/6 inhibitors in different settings and different patient subtypes. https://www.medscape.org/sites/advances/metastatic-breast-cancer